Cell News and Research

RSS

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Scientists analyze genetic networks of microRNAs in tumors

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships. Researchers are now discovering how biological networks change and are rewired in cancer.

6 May 2010

IBM embarks on multi-year research effort to better understand actions needed to improve human health

IBM today launched a multi-year research effort to connect and analyze enormous collections of data from a wide variety of sources in order to enable individuals, governments and businesses to better understand which actions to take to improve human health. The project will initially focus on solving the issue of childhood obesity.

6 May 2010

New tools developed to enrich cereal products with bioactive compounds

The bioactive compounds of cereals are concentrated in the peripheral layers of the grains (bran) but most of them have a low bio-accessibility. In the HEALTHGRAIN project of the European Union, new tools for process monitoring were developed that support commercial implementation of innovative milling techniques including partial grain debranning, fine grinding and classification of grain fractions, resulting in flours and ingredients with enhanced nutritional properties.

6 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

ViaCyte granted three new U.S. patents

ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents.

6 May 2010

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

Cancer researchers at Princess Margaret Hospital have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

New blood test could increase success of lung cancer drug erlotinib: Study

A new blood test could increase the success of a popular lung cancer drug called erlotinib by allowing doctors select which patients will react positively to the drug.

6 May 2010

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics, Inc. today announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population.

6 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Milk consumption does not cause renal cell cancer

While previous research had suggested that drinking milk was related to factors that may increase the risk of renal cell cancer, results of a recent study exploiting the genetic contribution to variation in milk consumption suggest that this may not be the case.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

ImmunoGen proposes underwritten common stock public offering

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 8,500,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty (30) day option to purchase up to 1,275,000 additional shares to cover over-allotments, if any.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

Forward's second-quarter gross profit up 50%

Forward Industries, Inc., a designer and distributor of custom carrying case solutions, today announced financial results for its second fiscal quarter ended March 31, 2010.

6 May 2010

Cell News and Research

Vical reports net loss of $8.5 million for first-quarter 2010

Scientists analyze genetic networks of microRNAs in tumors

IBM embarks on multi-year research effort to better understand actions needed to improve human health

New tools developed to enrich cereal products with bioactive compounds

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

ViaCyte granted three new U.S. patents

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

New blood test could increase success of lung cancer drug erlotinib: Study

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Bone marrow stem cells show promise in multiple sclerosis

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Milk consumption does not cause renal cell cancer

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

ImmunoGen proposes underwritten common stock public offering

Novocell is now ViaCyte

Forward's second-quarter gross profit up 50%

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics